Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 01-Apr-24 4:33 PM View:  | Paulson John Director | Valeant Pharmaceuticals Int... (BHC) | 29-Mar-24 | Grant | 5,890 | $10.61 | $62,492.90 | 3% 202.42K to 208.31K | |
| 01-Apr-24 4:31 PM View: | Icahn Brett Director | Valeant Pharmaceuticals Int... (BHC) | 29-Mar-24 | Grant | 3,122 | $10.61 | $33,124.40 | 3% 105.38K to 108.5K | |
| 01-Apr-24 4:29 PM View: | Wechsler Amy B Director | Valeant Pharmaceuticals Int... (BHC) | 29-Mar-24 | Grant | 647 | $10.61 | $6,864.67 | < 1% 169.26K to 169.91K | |
| 01-Apr-24 4:30 PM View: | Robertson Russel C Director | Valeant Pharmaceuticals Int... (BHC) | 29-Mar-24 | Grant | 2,945 | $10.61 | $31,246.40 | 1% 222.33K to 225.28K | |
| 04-Mar-24 4:16 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 04-Mar-24 | Sale (Planned) | 6,313 | $9.80 | $61,867.40 | (1%) 506.22K to 499.9K | |
| 04-Mar-24 4:19 PM View: | Appio Thomas Chief Executive Officer Director | Valeant Pharmaceuticals Int... (BHC) | 01-Mar-24 | Payment of Exercise | 116,982 | $9.89 | $1,156,950.00 | (8%) 1.49M to 1.37M | |
| 04-Mar-24 4:24 PM View: | Barresi John S SVP, Controller & CAO | Valeant Pharmaceuticals Int... (BHC) | 01-Mar-24 | Payment of Exercise | 3,188 | $9.89 | $31,529.30 | (3%) 110.25K to 107.06K | |
| 04-Mar-24 4:16 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 01-Mar-24 | Payment of Exercise | 24,243 | $9.89 | $239,763.00 | (5%) 530.46K to 506.22K | |
| 04-Mar-24 4:19 PM View: | Appio Thomas Chief Executive Officer Director | Valeant Pharmaceuticals Int... (BHC) | 29-Feb-24 | Grant | 519,328 | -- | -- | 54% 967.01K to 1.49M | |
| 04-Mar-24 4:24 PM View: | Barresi John S SVP, Controller & CAO | Valeant Pharmaceuticals Int... (BHC) | 29-Feb-24 | Grant | 39,126 | -- | -- | 55% 71.13K to 110.25K | |
| 04-Mar-24 4:16 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 29-Feb-24 | Grant | 147,536 | -- | -- | 39% 382.93K to 530.46K | |
| 02-Jan-24 4:15 PM View: | Wechsler Amy B Director | Valeant Pharmaceuticals Int... (BHC) | 29-Dec-23 | Grant | 857 | $8.02 | $6,873.14 | < 1% 168.4K to 169.26K | |
| 02-Jan-24 4:19 PM View: | Robertson Russel C Director | Valeant Pharmaceuticals Int... (BHC) | 29-Dec-23 | Grant | 3,896 | $8.02 | $31,245.90 | 2% 218.44K to 222.33K | |
| 02-Jan-24 4:16 PM View: | Paulson John Director | Valeant Pharmaceuticals Int... (BHC) | 29-Dec-23 | Grant | 7,793 | $8.02 | $62,499.90 | 4% 194.63K to 202.42K | |
| 02-Jan-24 4:18 PM View: | Icahn Brett Director | Valeant Pharmaceuticals Int... (BHC) | 29-Dec-23 | Grant | 4,130 | $8.02 | $33,122.60 | 4% 101.25K to 105.38K | |
| 05-Dec-23 4:35 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 05-Dec-23 | Sale (Planned) | 220 | $7.38 | $1,623.60 | (< 1%) 383.14K to 382.93K | |
| 05-Dec-23 4:35 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 01-Dec-23 | Payment of Exercise | 1,691 | $7.36 | $12,445.80 | (< 1%) 384.84K to 383.14K | |
| 06-Nov-23 5:06 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 06-Nov-23 | Sale (Planned) | 43 | $7.61 | $327.23 | (< 1%) 384.88K to 384.84K | |
| 06-Nov-23 5:06 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 03-Nov-23 | Payment of Exercise | 334 | $7.57 | $2,528.38 | (< 1%) 385.21K to 384.88K | |
| 02-Oct-23 4:29 PM View: | Wechsler Amy B Director | Valeant Pharmaceuticals Int... (BHC) | 29-Sep-23 | Grant | 836 | $8.22 | $6,871.92 | < 1% 167.57K to 168.4K | |
| 02-Oct-23 4:28 PM View: | Robertson Russel C Director | Valeant Pharmaceuticals Int... (BHC) | 29-Sep-23 | Grant | 3,801 | $8.22 | $31,244.20 | 2% 214.64K to 218.44K | |
| 02-Oct-23 4:27 PM View: | Paulson John Director | Valeant Pharmaceuticals Int... (BHC) | 29-Sep-23 | Grant | 7,603 | $8.22 | $62,496.70 | 4% 187.02K to 194.63K | |
| 02-Oct-23 4:25 PM View: | Icahn Brett Director | Valeant Pharmaceuticals Int... (BHC) | 29-Sep-23 | Grant | 4,029 | $8.22 | $33,118.40 | 4% 97.22K to 101.25K | |
| 06-Sep-23 4:33 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 06-Sep-23 | Sale (Planned) | 6,685 | $8.28 | $55,351.80 | (2%) 391.9K to 385.21K | |
| 06-Sep-23 4:31 PM View: | Barresi John S SVP, Controller & CAO | Valeant Pharmaceuticals Int... (BHC) | 05-Sep-23 | Payment of Exercise | 3,982 | $8.35 | $33,249.70 | (5%) 75.11K to 71.13K | |
| 06-Sep-23 4:29 PM View: | Vadaketh Tom George EVP, Chief Financial Officer | Valeant Pharmaceuticals Int... (BHC) | 05-Sep-23 | Payment of Exercise | 43,948 | $8.35 | $366,966.00 | (7%) 608.88K to 564.93K | |
| 06-Sep-23 4:33 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 05-Sep-23 | Payment of Exercise | 51,337 | $8.35 | $428,664.00 | (12%) 443.24K to 391.9K | |
| 05-Sep-23 5:09 PM View: | Appio Thomas Chief Executive Officer Director | Valeant Pharmaceuticals Int... (BHC) | 01-Sep-23 | Payment of Exercise | 14,111 | $8.46 | $119,379.00 | (1%) 981.12K to 967.01K | |
| 05-Jul-23 4:06 PM View: | Paulson John Director | Valeant Pharmaceuticals Int... (BHC) | 30-Jun-23 | Grant | 7,812 | $8.00 | $62,496.00 | 4% 179.21K to 187.02K | |
| 05-Jul-23 4:07 PM View: | Icahn Brett Director | Valeant Pharmaceuticals Int... (BHC) | 30-Jun-23 | Grant | 4,140 | $8.00 | $33,120.00 | 4% 93.08K to 97.22K | |
| 05-Jul-23 4:09 PM View: | Wechsler Amy B Director | Valeant Pharmaceuticals Int... (BHC) | 30-Jun-23 | Grant | 859 | $8.00 | $6,872.00 | < 1% 166.71K to 167.57K | |
| 05-Jul-23 4:01 PM View: | Robertson Russel C Director | Valeant Pharmaceuticals Int... (BHC) | 30-Jun-23 | Grant | 3,906 | $8.00 | $31,248.00 | 2% 210.73K to 214.64K | |
| 21-Jun-23 4:10 PM View: | Barresi John S SVP, Controller & CAO | Valeant Pharmaceuticals Int... (BHC) | 20-Jun-23 | Payment of Exercise | 1,929 | $7.40 | $14,274.60 | (3%) 77.04K to 75.11K | |
| 19-May-23 4:19 PM View: | Power Robert N Director | Valeant Pharmaceuticals Int... (BHC) | 19-May-23 | Grant | 29,205 | -- | -- | 22% 135.81K to 165.02K | |
| 19-May-23 4:16 PM View: | Mulligan Richard Director | Valeant Pharmaceuticals Int... (BHC) | 19-May-23 | Grant | 29,205 | -- | -- | 80% 36.7K to 65.91K | |
| 19-May-23 4:26 PM View: | Wechsler Amy B Director | Valeant Pharmaceuticals Int... (BHC) | 19-May-23 | Grant | 29,205 | -- | -- | 21% 137.5K to 166.71K | |
| 19-May-23 4:20 PM View: | Robertson Russel C Director | Valeant Pharmaceuticals Int... (BHC) | 19-May-23 | Grant | 29,205 | -- | -- | 16% 181.53K to 210.73K | |
| 19-May-23 4:24 PM View: | Ross Thomas W. Sr. Director | Valeant Pharmaceuticals Int... (BHC) | 19-May-23 | Grant | 29,205 | -- | -- | 22% 132.31K to 161.52K | |
| 19-May-23 4:13 PM View: | Kavanagh Sarah B Director | Valeant Pharmaceuticals Int... (BHC) | 19-May-23 | Grant | 29,205 | -- | -- | 25% 117.45K to 146.65K | |
| 19-May-23 4:14 PM View: | Miller Steven D Director | Valeant Pharmaceuticals Int... (BHC) | 19-May-23 | Grant | 29,205 | -- | -- | 24% 120.31K to 149.52K | |
| 19-May-23 4:27 PM View: | Paulson John Director | Valeant Pharmaceuticals Int... (BHC) | 19-May-23 | Grant | 29,205 | -- | -- | 19% 150.01K to 179.21K | |
| 19-May-23 4:11 PM View: | Icahn Brett Director | Valeant Pharmaceuticals Int... (BHC) | 19-May-23 | Grant | 29,205 | -- | -- | 46% 63.87K to 93.08K | |
| 04-Apr-23 6:07 PM View: | Wechsler Amy B Director | Valeant Pharmaceuticals Int... (BHC) | 31-Mar-23 | Grant | 848 | $8.10 | $6,868.80 | < 1% 136.65K to 137.5K | |
| 04-Apr-23 6:06 PM View: | Robertson Russel C Director | Valeant Pharmaceuticals Int... (BHC) | 31-Mar-23 | Grant | 4,110 | $8.10 | $33,291.00 | 2% 177.42K to 181.53K | |
| 04-Apr-23 6:02 PM View: | de Schutter Richard U Director | Valeant Pharmaceuticals Int... (BHC) | 31-Mar-23 | Grant | 3,642 | $8.10 | $29,500.20 | < 1% 383.56K to 387.21K | |
| 04-Apr-23 6:04 PM View: | Paulson John Director | Valeant Pharmaceuticals Int... (BHC) | 31-Mar-23 | Grant | 7,716 | $8.10 | $62,499.60 | 5% 142.29K to 150.01K | |
| 04-Apr-23 6:03 PM View: | Icahn Brett Director | Valeant Pharmaceuticals Int... (BHC) | 31-Mar-23 | Grant | 3,684 | $8.10 | $29,840.40 | 6% 60.19K to 63.87K | |
| 06-Mar-23 4:52 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 06-Mar-23 | Payment of Exercise | 495 | $9.17 | $4,539.15 | (< 1%) 443.73K to 443.24K | |
| 06-Mar-23 4:49 PM View: | Appio Thomas Chief Executive Officer Director | Valeant Pharmaceuticals Int... (BHC) | 03-Mar-23 | Payment of Exercise | 10,175 | $9.16 | $93,203.00 | (1%) 991.3K to 981.12K | |
| 06-Mar-23 4:52 PM View: | Carson Seana EVP, General Counsel | Valeant Pharmaceuticals Int... (BHC) | 03-Mar-23 | Payment of Exercise | 780 | $9.34 | $7,285.20 | (< 1%) 444.51K to 443.73K |
